Heerspink, Hiddo J. L; Sjostrom, C. David; Jongs, Niels; Chertow, Glenn M; Kosiborod, Mikhail; Hou, Fan Fan; McMurray, John J; Rossing, Peter; Correa-Rotter, Ricardo; Kurlyandskaya, Raisa; Noronha, Irene de Lourdes 
Source: European heart journal. Unidade: FM
Subjects: DOENÇA CRÔNICA, INSUFICIÊNCIA RENAL, MORTALIDADE, ESTUDOS RANDOMIZADOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEERSPINK, Hiddo J. L et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. European heart journal, v. 42, n. 13, p. 1216-1227, 2022Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehab094. Acesso em: 09 nov. 2024.APA
Heerspink, H. J. L., Sjostrom, C. D., Jongs, N., Chertow, G. M., Kosiborod, M., Hou, F. F., et al. (2022). Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. European heart journal, 42( 13), 1216-1227. doi:10.1093/eurheartj/ehab094NLM
Heerspink HJL, Sjostrom CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJ, Rossing P, Correa-Rotter R, Kurlyandskaya R, Noronha I de L. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial [Internet]. European heart journal. 2022 ; 42( 13): 1216-1227.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1093/eurheartj/ehab094Vancouver
Heerspink HJL, Sjostrom CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJ, Rossing P, Correa-Rotter R, Kurlyandskaya R, Noronha I de L. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial [Internet]. European heart journal. 2022 ; 42( 13): 1216-1227.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1093/eurheartj/ehab094
